Paper42428494
Targeting ferroptosis in osteoporosis: mechanisms and natural products therapies.
Cao Z and 4 others. Front Pharmacol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Targeting ferroptosis in osteoporosis: mechanisms and natural products therapies. Papers, record 42428494. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42428494
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References214
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29378199 | Iron-induced oxidative stress stimulates osteoclast differentiation via NF-κB signaling pathway in mouse model. | Metabolism | 2018 | https://conductscience.org/library/papers/29378199 | PubMed |
| 2 | 31949885 | Curculigoside Protects against Excess-Iron-Induced Bone Loss by Attenuating Akt-FoxO1-Dependent Oxidative Damage to Mice and Osteoblastic MC3T3-E1 Cells. | Oxid Med Cell Longev | 2019 | https://conductscience.org/library/papers/31949885 | PubMed |
| 3 | 41551515 | The role of ferroptosis in osteoporosis: from pathogenic mechanisms to natural product-driven therapeutic innovations. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/41551515 | PubMed |
| 4 | 35863612 | Promising traditional Chinese medicine for the treatment of cholestatic liver disease process (cholestasis, hepatitis, liver fibrosis, liver cirrhosis). | J Ethnopharmacol | 2022 | https://conductscience.org/library/papers/35863612 | PubMed |
| 5 | 40515876 | Ferroptosis: Disease Associations and Therapeutic Target Exploration. | J Mol Neurosci | 2025 | https://conductscience.org/library/papers/40515876 | PubMed |
| 6 | 41003973 | Salidroside and inflammation-linked disorders: integrative insights into the pharmacological effects and mechanistic targets. | Inflammopharmacology | 2025 | https://conductscience.org/library/papers/41003973 | PubMed |
| 7 | 41036508 | Forsythiaside A Suppresses Ferroptosis and Mitigates Type 2 Diabetes Osteoporosis Through the NRF2/GPX4 Axis. | Food Sci Nutr | 2025 | https://conductscience.org/library/papers/41036508 | PubMed |
| 8 | 38569557 | A clinical-stage Nrf2 activator suppresses osteoclast differentiation via the iron-ornithine axis. | Cell Metab | 2024 | https://conductscience.org/library/papers/38569557 | PubMed |
| 9 | 41115354 | Salidroside alleviates senile osteoporosis in SAMP8 mice by inhibiting the ferroptosis of bone marrow stromal cells via PI3K/AKT/mTOR signaling pathway. | Int Immunopharmacol | 2025 | https://conductscience.org/library/papers/41115354 | PubMed |
| 10 | 38081572 | Niacin treatment prevents bone loss in iron overload osteoporotic rats via activation of SIRT1 signaling pathway. | Chem Biol Interact | 2024 | https://conductscience.org/library/papers/38081572 | PubMed |
| 11 | 39823248 | Aucubin Promotes BMSCs Proliferation and Differentiation of Postmenopausal Osteoporosis Patients by Regulating Ferroptosis and BMP2 Signalling. | J Cell Mol Med | 2025 | https://conductscience.org/library/papers/39823248 | PubMed |
| 12 | 38142661 | Exploring the boost of steaming with wine on Ligustri Lucidi Fructus in treating postmenopausal osteoporosis based on superior "multi-component structure" and iron/bone metabolism coregulation. | Phytomedicine | 2024 | https://conductscience.org/library/papers/38142661 | PubMed |
| 13 | 32065376 | Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review. | Adv Ther | 2020 | https://conductscience.org/library/papers/32065376 | PubMed |
| 14 | 34360948 | The Development of Molecular Biology of Osteoporosis. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34360948 | PubMed |
| 15 | 35713852 | Astragalus polysaccharide: a review of its immunomodulatory effect. | Arch Pharm Res | 2022 | https://conductscience.org/library/papers/35713852 | PubMed |
| 16 | 35638167 | Iron overload-induced ferroptosis of osteoblasts inhibits osteogenesis and promotes osteoporosis: An in vitro and in vivo study. | IUBMB Life | 2022 | https://conductscience.org/library/papers/35638167 | PubMed |
| 17 | 35508203 | Molecular Mechanisms of Iron and Heme Metabolism. | Annu Rev Nutr | 2022 | https://conductscience.org/library/papers/35508203 | PubMed |
| 18 | 40245968 | Qing'e Pill rectifies bone homeostasis imbalance in diabetic osteoporosis via the AGE/RAGE pathway: A network pharmacology analysis and multi-omics validation. | J Ethnopharmacol | 2025 | https://conductscience.org/library/papers/40245968 | PubMed |
| 19 | 40416706 | Ferroptosis: New Strategies for Clinical Treatment of Rheumatoid Arthritis. | J Inflamm Res | 2025 | https://conductscience.org/library/papers/40416706 | PubMed |
| 20 | 40488210 | Picroside II regulates the YY1/TGFβ1 axis by inhibiting osteoblast ferroptosis to alleviate symptoms of postmenopausal osteoporosis. | Cytotechnology | 2025 | https://conductscience.org/library/papers/40488210 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42428494
GET https://conductscience.org/api/papers/v1/42428494/references?page=2